Cargando…

Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome

OBJECTIVE: We report an outbreak of Achromobacter xylosoxidans at a neonatal intensive care unit. We aimed to present clinical, laboratory and treatment data of the patients. MATERIALS AND METHODS: All consecutive episodes of bacteremia due to A. xylosoxidans at our neonatal intensive care unit, beg...

Descripción completa

Detalles Bibliográficos
Autores principales: Turel, Ozden, Kavuncuoglu, Sultan, Hosaf, Emine, Ozbek, Sibel, Aldemir, Esin, Uygur, Turkan, Hatipoglu, Nevin, Siraneci, Rengin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428061/
https://www.ncbi.nlm.nih.gov/pubmed/23742802
http://dx.doi.org/10.1016/j.bjid.2013.01.008
_version_ 1784779034720206848
author Turel, Ozden
Kavuncuoglu, Sultan
Hosaf, Emine
Ozbek, Sibel
Aldemir, Esin
Uygur, Turkan
Hatipoglu, Nevin
Siraneci, Rengin
author_facet Turel, Ozden
Kavuncuoglu, Sultan
Hosaf, Emine
Ozbek, Sibel
Aldemir, Esin
Uygur, Turkan
Hatipoglu, Nevin
Siraneci, Rengin
author_sort Turel, Ozden
collection PubMed
description OBJECTIVE: We report an outbreak of Achromobacter xylosoxidans at a neonatal intensive care unit. We aimed to present clinical, laboratory and treatment data of the patients. MATERIALS AND METHODS: All consecutive episodes of bacteremia due to A. xylosoxidans at our neonatal intensive care unit, beginning with the index case detected at November 2009 until cessation of the outbreak in April 2010, were evaluated retrospectively. RESULTS: Thirty-four episodes of bacteremia occurred in 22 neonates during a 6-month period. Among the affected, 90% were preterm newborns with gestational age of 32 weeks or less and 60% had birth weight of 1000 g or less. Endotracheal intubation, intravenous catheter use, total parenteral nutrition and prolonged antibiotic therapy were the predisposing conditions. Presenting features were abdominal distention, thrombocytopenia and neutropenia. The mortality rate was 13.6% and the majority of isolates were susceptible to piperacillin-tazobactam, carbapenems and trimethoprim-sulfametoxazole, and resistant to gentamycin. More than half were breakthrough infections. Despite intensive efforts to control the outbreak by standard methods of hand hygiene, patient screening and isolation, containment could be achieved only after the neonatal intensive care unit was relocated. The investigation was not able to single out the source of the outbreak. CONCLUSION: A. xylosoxidans has the potential to cause serious infections in premature babies. More studies are needed to determine the importance of different sources of infection in hospital units.
format Online
Article
Text
id pubmed-9428061
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94280612022-09-01 Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome Turel, Ozden Kavuncuoglu, Sultan Hosaf, Emine Ozbek, Sibel Aldemir, Esin Uygur, Turkan Hatipoglu, Nevin Siraneci, Rengin Braz J Infect Dis Original Article OBJECTIVE: We report an outbreak of Achromobacter xylosoxidans at a neonatal intensive care unit. We aimed to present clinical, laboratory and treatment data of the patients. MATERIALS AND METHODS: All consecutive episodes of bacteremia due to A. xylosoxidans at our neonatal intensive care unit, beginning with the index case detected at November 2009 until cessation of the outbreak in April 2010, were evaluated retrospectively. RESULTS: Thirty-four episodes of bacteremia occurred in 22 neonates during a 6-month period. Among the affected, 90% were preterm newborns with gestational age of 32 weeks or less and 60% had birth weight of 1000 g or less. Endotracheal intubation, intravenous catheter use, total parenteral nutrition and prolonged antibiotic therapy were the predisposing conditions. Presenting features were abdominal distention, thrombocytopenia and neutropenia. The mortality rate was 13.6% and the majority of isolates were susceptible to piperacillin-tazobactam, carbapenems and trimethoprim-sulfametoxazole, and resistant to gentamycin. More than half were breakthrough infections. Despite intensive efforts to control the outbreak by standard methods of hand hygiene, patient screening and isolation, containment could be achieved only after the neonatal intensive care unit was relocated. The investigation was not able to single out the source of the outbreak. CONCLUSION: A. xylosoxidans has the potential to cause serious infections in premature babies. More studies are needed to determine the importance of different sources of infection in hospital units. Elsevier 2013-06-03 /pmc/articles/PMC9428061/ /pubmed/23742802 http://dx.doi.org/10.1016/j.bjid.2013.01.008 Text en © 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Turel, Ozden
Kavuncuoglu, Sultan
Hosaf, Emine
Ozbek, Sibel
Aldemir, Esin
Uygur, Turkan
Hatipoglu, Nevin
Siraneci, Rengin
Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title_full Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title_fullStr Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title_full_unstemmed Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title_short Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome
title_sort bacteremia due to achromobacter xylosoxidans in neonates: clinical features and outcome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428061/
https://www.ncbi.nlm.nih.gov/pubmed/23742802
http://dx.doi.org/10.1016/j.bjid.2013.01.008
work_keys_str_mv AT turelozden bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT kavuncuoglusultan bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT hosafemine bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT ozbeksibel bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT aldemiresin bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT uygurturkan bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT hatipoglunevin bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome
AT siranecirengin bacteremiaduetoachromobacterxylosoxidansinneonatesclinicalfeaturesandoutcome